AHL Partners’s Kyntra Bio KYNB Stock Holding History

AHL Partners’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-439	Closed	-$590K	–	1289
2017 Q3	$590K	Buy	+439	New	+$463K	0.01%	1011

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

AHL Partners's KYNB Position: Q4 2017 in Review

AHL Partners sold out of Kyntra Bio (KYNB) in Q4 2017, closing a stake of 439 shares — an estimated $590K sold.

AHL Partners first reported a position in KYNB in Q3 2017 and held it in 1 quarter. The position peaked at $590K in Q3 2017. 187 funds tracked by Wall St. Rank hold KYNB as of Q4 2017.

AHL Partners reported no remaining Kyntra Bio position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 439 Kyntra Bio shares in Q4 2017, an estimated $590K.
AHL Partners first reported a position in Kyntra Bio in Q3 2017 and held it in 1 quarter.
AHL Partners's Kyntra Bio position peaked at $590K in Q3 2017.
187 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.